Clinical trial
The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients
NCT00002385 · Anderson Clinical Research, Industry · Completed
Key facts
| NCT number | NCT00002385 |
|---|---|
| Title | The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients |
| Official title | Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314). |
| Lead sponsor | Anderson Clinical Research, Industry |
| Collaborators | Boehringer Mannheim Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Fozivudine tidoxil |
| Enrollment | 60 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: